In fact, according to one report, 50% of HIV patie
Post# of 148279
Gestalt suggested that we might get 10% of the HIV market. Seems entirely reasonable.
So when suncloud says "our trial was for MDR or multi drug resistant patients which would not include all patients just those who failed with multiple other treatments," this is a far larger group than Gestalt's 10%.
There is still an HIV market for Leron.